Fig. 7

a Relative expression of GRM5 in the normal and induced groups from week 1 to week 3. b Relative expression of GRM5 in the agomiR-NC, agomiR-miR-129-5p, agomiR-129-5p+pcDNA3.1-GEM5, antagomiR-NC, antagomiR-miR-129-5p, and antagomiR-miR-129-5p+sh-GRM5 groups. c Binding site of miR-129-5p and the wt/mut GRM5 3′UTR. d Luciferase activity (GRM5 3′UTR wt and GRM5 3′UTR mut) in agomiR-NC- and agomiR-miR-129-5p-transfected cells. e Relative expression of Runx2, Osterix, and osteocalcin in the agomiR-NC, agomiR-miR-129-5p, agomiR-129-5p+pcDNA3.1-GEM5, antagomiR-NC, antagomiR-miR-129-5p, and antagomiR-miR-129-5p+sh-GRM5 groups. f Western blot analysis of Runx2, Osterix, and osteocalcin in the agomiR-NC, agomiR-miR-129-5p, agomiR-129-5p+pcDNA3.1-GEM5, antagomiR-NC, antagomiR-miR-129-5p, and antagomiR-miR-129-5p+sh-GRM5 groups. g ARS and ALP staining in the transfection groups. **P < 0.01, compared with the NC group; ^##P < 0. 01, compared with the sh-NC group